RELATIVITY-047: Phase II/III Trial of First-line Relatlimab + Nivolumab vs Nivolumab Alone in Advanced Melanoma

Dr Evan J. Lipson shares expert insights on the safety and efficacy of anti-LAG-3 immunotherapies in this webcast from Clinical Care Options (CCO)

Evan J. Lipson, MD Tian Zhang, MD, MHS Physicians: maximum of 0.75 AMA PRA Category 1 Credits™ Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: April 20, 2022 Expired: April 19, 2023

Downloadable slideset on targeting LAG-3 in multiple tumor types and evidence on recently approved LAG-3 therapy, relatlimab, from Clinical Care Options (CCO)

Evan J. Lipson, MD Tian Zhang, MD, MHS Released: March 23, 2022

Downloadable PDF resource on LAG-3, safety and efficacy of approved anti-LAG-3 agent relatlimab, and clinical trial spotlight from Clinical Care Options (CCO)

Krista M. Rubin, MS, RN, FNP-BC Released: March 23, 2022

Downloadable slideset explaining the mechanism of action of LAG-3, from Clinical Care Options (CCO)